











# Pediatric COVID-19 Vaccine Dosing Quick Reference Guide

## Moderna, Pfizer-BioNTech, and Novavax COVID-19 Vaccine Products



Moderna COVID-19 Vaccine Products 2025–2026 Formula			Pfizer-BioNTech COVID-19 Vaccine Products 2025–2026 Formula		Novavax COVID-19 Vaccine Product 2025–2026 Formula
<b>Spikevax (red label)</b> 6 months–11 years	<b>Spikevax (blue label)</b> 12 years and older	<b>mNEXSPIKE (teal label)</b> 12 years and older	<b>Comirnaty (blue cap)</b> 5–11 years	<b>Comirnaty (gray label)</b> 12 years and older	<b>Nuvaxovid (dark cyan label)</b> 12 years and older
 0.25 ml single-dose prefilled syringe	 0.5 ml single-dose prefilled syringe	 0.2 ml single-dose prefilled syringe	 10 mcg/0.3 ml single-dose vial	 0.3 ml single-dose prefilled syringe	 0.5 ml single-dose prefilled syringe



<sup>a</sup> For children who turn 2 during their vaccine series, complete the initial series using the recommended schedule as outlined for individuals 6–23 months.

<sup>b</sup> An 8-week interval between the first and second COVID-19 vaccine doses might be optimal for some people as it might reduce the rare risk of myocarditis and pericarditis associated with these vaccines.







# Pediatric COVID-19 Vaccine Dosing Quick Reference Guide




Moderna, Pfizer-BioNTech, and Novavax COVID-19 Vaccine Products for Individuals who are Moderately or Severely Immunocompromised

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN®



Moderna COVID-19 Vaccine Products 2025–2026 Formula			Pfizer-BioNTech COVID-19 Vaccine Products 2025–2026 Formula		Novavax COVID-19 Vaccine Product 2025–2026 Formula
<b>Spikevax (red label)</b> 6 months–11 years	<b>Spikevax (blue label)</b> 12 years and older	<b>mNEXSPIKE (teal label)</b> 12 years and older	<b>Comirnaty (blue cap)</b> 5–11 years	<b>Comirnaty (gray label)</b> 12 years and older	<b>Nuvaxovid (dark cyan label)</b> 12 years and older
					
0.25 ml single-dose prefilled syringe	0.5 ml single-dose prefilled syringe	0.2 ml single-dose prefilled syringe	10 mcg/0.3 ml single-dose vial	0.3 ml single-dose prefilled syringe	0.5 ml single-dose prefilled syringe



**a.** For children who turn 4 to 5 years during their vaccine series, follow dosing recommendations based on age on the day of vaccination.

**b.** Individuals who are moderately or severely immunocompromised should receive one additional age-appropriate dose of 2025–2026 COVID vaccine from any manufacturer 6 months following the last recommended 2025–2026 dose (minimum interval 2 months).

**c.** COVID-19 vaccine doses from the same manufacturer should be administered whenever recommended. In the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered: (1) Same vaccine not available at the vaccination site at the time of the clinic visit, (2) Previous dose unknown, (3) Person would otherwise not receive a recommended vaccine dose, (4) Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication. A [Vaccine Adverse Event Reporting System \(VAERS\)](#) report is not indicated in these circumstances.

**d.** Individuals who are moderately or severely immunocompromised may receive further additional doses at ≥ 2 month intervals, informed by clinical judgment of a healthcare provider and personal preference and circumstances. Individuals 5 years and older may receive any age-appropriate 2025–2026 COVID vaccine for all additional doses, regardless of manufacturer for the initial series.

**e.** For children who turn 11 to 12 years during their vaccine series, follow dosing recommendations based on age at the time of vaccination.